Search
Abdavomeran
go.drugbank.com/drugs/DB15695Investigational[L15017, L15022] BNT162b1 received fast track designation by the FDA on July 13, 2020.[L15027] … volunteers demonstrated RBD-binding immunoglobulin levels and 50% serum neutralizing titers higher than those observed in [COVID-19 convalescent plasma] 28 days after initial immunization of either 10 or 30μg
Auranofin
go.drugbank.com/drugs/DB00995ApprovedInvestigationalIt has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA.
Isoprenaline
go.drugbank.com/drugs/DB01064ApprovedInvestigationalIsoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, a...
Necitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnIt functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression
Casimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigationalCasimersen is currently marketed under the tradename AMONDYS 45™ by Sarepta Therapeutics, Inc.[L32118] … However, the specific mutations, and hence the precise exon skipping, targeted by each is different.
Sinapultide
go.drugbank.com/drugs/DB11332ApprovedWithdrawnThis large disadvantage was overcome with animal-derived surfactant products which contain specific proteins but are limited, but must be derived from animal sources. … [L2506] The product was originally developed by the Scripps Research Institute, then licensed to Windtree Therapeutics.
Cocoa butter
go.drugbank.com/drugs/DB11086ApprovedFat cocoa solids, including cocoa butter, have lower phenolic content than non-fat cocoa solids but may contain some polyphenols of different structures of flavonoids with antioxidant properties [A33041 … It is a rich source of monounsaturated and saturated fatty acids [A33040] that mainly contains approximately 33% [DB04224], 25% [DB03796], and 33% [DB03193] [A20409] but does not contain caffeine or theobromine
Prasugrel
go.drugbank.com/drugs/DB06209ApprovedInvestigationalPrasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary
Products: EFIENT 10MG, EFIENT 10MG FTARepaglinide
go.drugbank.com/drugs/DB00912ApprovedInvestigationalThe average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release.
Elotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalElotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. … Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S.